Skip to main content
Office of the Dean

Office of the Dean

NEWS | October 17, 2012

UC Davis researchers clarify process controlling night vision

(SACRAMENTO, Calif.)

On the road at night or on a tennis court at dusk, the eye can be deceived. Vision is not as sharp as in the light of day, and detecting a bicyclist on the road or a careening tennis ball can be tough.

Scanning electron micrograph of rod photoreceptors lining the surface of a mouse retina.  These small, noodle-like compartments of the cells are filled with proteins that absorb photons of light and generate the first steps in seeing © UC Regents. Scanning electron micrograph of rod photoreceptors lining the surface of a mouse retina. These small, noodle-like compartments of the cells are filled with proteins that absorb photons of light and generate the first steps in seeing © UC Regents.

New research reveals the key chemical process that corrects for potential visual errors in low-light conditions. Understanding this fundamental step could lead to new treatments for visual deficits, or might one day boost normal night vision to new levels.

Like the mirror of a telescope pointed toward the night sky, the eye's rod cells capture the energy of photons ― the individual particles that make up light. The interaction triggers a series of chemical signals that ultimately translate the photons into the light we see.

The key light receptor in rod cells is a protein called rhodopsin. Each rod cell has about 100 million rhodopsin receptors, and each one can detect a single photon at a time.

Scientists had thought that the strength of rhodopsin's signal determines how well we see in dim light. But UC Davis scientists have found instead that a second step acts as a gatekeeper to correct for rhodopsin errors. The result is a more accurate reading of light under dim conditions.

A report on their research appears in the October issue of the journal Neuron in a study entitled "Calcium feedback to cGMP synthesis strongly attenuates single photon responses driven by long rhodopsin lifetimes."

Individual rhodopsin errors are relatively small in magnitude ― on the order of a few hundredths of a second ― but even this much biological noise can affect how well the signal gets transmitted to the rest of the brain, the researchers said. 

The gatekeeper protects us from "seeing" more light than is actually there ― a misreading that would have endangered an ice-age hunter, as it would a driver at dusk today. The correction may prevent the photon receptor from swamping the intricate chemical apparatus that leads to accurate light perception.

"The rhodopsin receptor is the site where physics meets biology ― where a photon of light from the physical world must get interpreted for the nervous system," said Marie Burns, professor of ophthalmology and vision science at UC Davis School of Medicine and lead author of the study. "Biology is messy. Rhodopsin does a remarkable but not perfect job."

Burns and her colleagues studied rod cells in the laboratory and discovered that calcium plays the gatekeeper role. 

They found that rhodopsin activity changed calcium levels in the cells and that over-active rhodopsins changed calcium levels at a faster rate than normal. This faster change led calcium to trigger a series of chemical steps to counter the over-active rhodopsin signal by producing an equal and opposite signal, thereby correcting false information before it gets sent on to the rest of the visual system.

They uncovered this fundamental new level of control by measuring how long individual rhodopsin receptors remained active in response to flashes of light, and then determining how much calcium's gatekeeping function modified the rhodopsin signals.

"Basic research like ours often doesn't translate to immediate clinical treatments for known diseases, but understanding fundamental processes has long-term significance," Burns said. "In the case of our research, this understanding can prove  essential for progress on a range of vision deficits that are currently poorly understood and untreatable."

Colleagues in the research and co-authors on the paper include Owen Gross, a former doctoral student at UC Davis who is now at Oregon Health Sciences University, and Edward N. Pugh Jr., a professor in the Department of Cell Biology and Human Anatomy and Department of Physiology and Membrane Biology at the UC Davis School of Medicine. 

The research was funded with a grant from the National Eye Institute.

UC Davis Health System is improving lives and transforming health care by providing excellent patient care, conducting groundbreaking research, fostering innovative, interprofessional education, and creating dynamic, productive partnerships with the community. The academic health system includes one of the country's best medical schools, a 619-bed acute-care teaching hospital, a 1000-member physician's practice group and the new Betty Irene Moore School of Nursing. It is home to a National Cancer Institute-designated comprehensive cancer center, an international neurodevelopmental institute, a stem cell institute and a comprehensive children's hospital. Other nationally prominent centers focus on advancing telemedicine, improving vascular care, eliminating health disparities and translating research findings into new treatments for patients. Together, they make UC Davis a hub of innovation that is transforming health for all. For more information, visit healthsystem.ucdavis.edu.